logo
logo

Reify Health Raises $220M Series D To Bridge The Diversity Gap In Clinical Trials

Apr 21, 2022•about 3 years ago

Amount Raised

$220 Million

Round Type

series d

Boston

Description

Reify Health, a leading provider of solutions that empower the clinical trial ecosystem, today announced a $220M Series D round co-led by Altimeter Capital and Coatue, joined by Dragoneer Investment Group and existing investors ICONIQ Growth, Adams Street, and Battery Ventures. This round of funding, which brings the company’s valuation to over $4.8 billion, was secured to accelerate the company’s efforts to improve diversity and representation in clinical trial participation.

Company Information

Company

Reify Health

Location

Boston, Massachusetts, United States

About

Reify Health paves the way to faster, predictable, and more accessible clinical trials. Through its business entities, StudyTeam and Care Access, the company provides best-in-class clinical optimization software, with a focus on effective enrollment, and transformative clinical trial infrastructure that delivers research directly to more healthcare providers, communities, and patients wherever they are. Through partnerships with top biopharma companies, leading healthcare organizations, and thousands of research sites worldwide, Reify Health eliminates delays in drug development one trial at a time. To find out how Reify Health makes clinical research better, faster, and more collaborative, visit www.reifyhealth.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People